CD274 and pneumonitis: Previous studies have identified several risk factors for pneumonitis in patients with lung cancer treated with pembrolizumab monotherapy, including pre‐existing lung conditions, prior radiation therapy, older age, lower performance status, and higher PD‐L1 expression status.26, 27, 28, 29